Akamai (AKAM) CTO sells 3,500 shares at $97 under 10b5-1 plan

Rhea-AI Filing Summary

Akamai Technologies’ Chief Technology Officer Dr. Robert Blumofe reported a planned stock sale under a Rule 10b5-1 trading plan. On January 22, 2026, he sold 3,500 shares of Akamai common stock at a price of $97 per share under a 10b5-1 plan adopted on March 12, 2025. After this transaction, he beneficially owned 18,074 shares directly, and an additional 90.985 shares indirectly through a 401(k) plan as of January 22, 2026.

Insider Trade Summary

Net Seller: 3,500 shares ($339,500)

Net Sell 2 txns

Insider Blumofe Robert

Role Chief Technology Officer

Sold 3,500 shs ($340K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,500	$97.00	$340K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 18,074 shares (Direct); Common Stock — 90.985 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. Sale was made pursuant to a Rule 10b5-1 Plan adopted by Dr. Blumofe on March 12, 2025. As of January 22, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blumofe Robert

(Last) (First) (Middle)

C/O AKAMAI TECHNOLOGIES, INC.

145 BROADWAY

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AKAMAI TECHNOLOGIES INC [ AKAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		3,500	D	$97	18,074	D
Common Stock								90.985(2)	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was made pursuant to a Rule 10b5-1 Plan adopted by Dr. Blumofe on March 12, 2025.

2. As of January 22, 2026.

Remarks:

	/s/ Thomas M. Lair, as power of attorney	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trade did Akamai (AKAM) report for its CTO on January 22, 2026?

On January 22, 2026, Akamai Technologies’ Chief Technology Officer Dr. Robert Blumofe sold 3,500 shares of Akamai common stock at $97 per share.

Was the Akamai (AKAM) CTO’s January 2026 share sale pre-planned?

Yes. The sale of 3,500 Akamai shares was made under a Rule 10b5-1 trading plan adopted by Dr. Robert Blumofe on March 12, 2025.

How many Akamai (AKAM) shares does the CTO hold after this Form 4 transaction?

After the reported sale, Dr. Robert Blumofe beneficially owned 18,074 shares of Akamai common stock directly and 90.985 shares indirectly through a 401(k) plan as of January 22, 2026.

What position does the insider in this Akamai (AKAM) Form 4 hold?

The reporting person in this Form 4, Dr. Robert Blumofe, serves as Chief Technology Officer of Akamai Technologies.

Does this Akamai (AKAM) Form 4 show direct or indirect ownership for the reported sale?

The sale of 3,500 Akamai common shares was reported as direct ownership (D), while an additional 90.985 shares are held indirectly through a 401(k) plan.

What date are the Akamai (AKAM) CTO’s remaining holdings reported as of?

The remaining direct and indirect holdings for Dr. Robert Blumofe are stated as of January 22, 2026.